ESCRS - PO290 - 10-Year Experience With Lamellar Keratoplasty For The Surgical Management Of Paediatric Corneal Diseases

10-Year Experience With Lamellar Keratoplasty For The Surgical Management Of Paediatric Corneal Diseases

Published 2022 - 40th Congress of the ESCRS

Reference: PO290 | Type: Free paper | DOI: 10.82333/9sb3-2f58

Authors: Andrea Sollazzo* 1 , Luca Furiosi 2 , Marco Pellegrini 2 , Rossella Spena 2 , Cristina Bovone 2 , Massimo Busin 2

1Department of Ophthalmology,Ospedali Privati Forlì "Villa Igea",Forlì,Italy, 2Department of Ophthalmology,Ospedali Privati Forlì "Villa Igea",Forlì,Italy;Department of Translational Medicine,University of Ferrara,Ferrara,Italy

Purpose

To evaluate the outcomes of various lamellar keratoplasty techniques performed at our Institution in children aged 14 years or younger over the last decade. 

Setting

Tertiary Eye Care Referral Center (Ospedali Privati Forlì “Villa Igea”, Forlì, Italy)

Methods

This single-center study reviewed 72 eyes that underwent lamellar keratoplasty for various indications. Deep anterior lamellar keratoplasty (DALK) was performed in 19 eyes, mushroom penetrating keratoplasty (PK) in 27 eyes and Descemet stripping automated endothelial keratoplasty (DSAEK) in 26 eyes. The main outcome measures included best spectacle-corrected visual acuity (BSCVA), complications and rate of graft failure which was defined as any graft requiring repeat transplantation. 

Results

BSCVA significantly improved after DALK, mushroom PK and DSAEK (all P <0.05), with 50%, 60% and 55% of eyes reaching ≥ 20/40, respectively. Stromal rejection was observed in 1 eye (5.3%) after DALK, whilst endothelial rejection occurred in 1 eye after mushroom PK (3.7%) and 1 eye after mushroom PK (3.8%). Overall survival was 100% after DALK (mean follow-up: 23.0 months), 92.8% after mushroom PK (mean follow-up: 42.3 months) and 96.2% after DSAEK  (mean follow-up: 32.3 months). 

Conclusions

DALK, mushroom PK and DSAEK offer good visual outcomes for children with corneal pathology, with low rates of immunological rejection and graft failure.